Spanish Chinese Russian German French Japanese Portuguese Hindi Telugu Tamil
Flyer

Health Science Journal

  • ISSN: 1108-7366
  • Journal h-index: 51
  • Journal CiteScore: 10.69
  • Journal Impact Factor: 9.13
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Google Scholar citation report
Citations : 12326

Health Science Journal received 12326 citations as per Google Scholar report

Flyer image
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
View More
Share This Page

Anti-IL4R���± Treatment in Patients Affected by Chronic Rhinosinusitis with Nasal Polyps and Asthma: a New Therapeutic Scenario

XX Congresso Regionale FADOI CAMPANIA: Non ci siamo mai fermati
Italy 2021

Brancaccio R*, Gigante L, Delfino G, Florio G and Patella V

Department of Internal Medicine ASL Salerno, �?�?�?¢�?�?�?�?�?�?�?�?Santa Maria della Speranza�?�?�?¢�?�?�?�?�?�?�? Hospital, Salerno, Italy
Postgraduate Program in Allergy and Clinical Immunology, University of Naples Federico II, Naples, Italy

Posters & Accepted Abstracts: Health Sci J

Abstract:

Background and aims: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is characterized by an heavy symptomatic burden and low quality of life (QoL). CRSwNP shows a type 2 inflammatory background, including high levels of IL-4 and IL-13. Sharing the same physiopathology, asthma is a common comorbidity of CRSwNP. When associated, asthma and CRSwNP have both a worse prognosis [1]. Dupilumab is a monoclonal antibody inhibiting IL-4 and IL-13 [2]. The aim of this study is evaluating anti-IL4Rα treatment in CRSwNP with asthma comorbidity in real life. Materials/Patients: 10 patients affected by CRSwNP and asthma (≥18 years, mean 36,6±14,7, 7M and 3F) were recruited. Methods: Every patient underwent a treatment with dupilumab according to data sheet. At the beginning of treatment (T0) and 16 weeks after (T1) TENPS, SNOT-22, FEV1 e ACT were evaluated. Results: SNOT-22 [T0=42,0 ± 23,9; T1=17 ± 6,2; -25 (-59,5%) p<0,001]; TENPS [T0=4,5 ± 2,1; T1= 2,0 ± 1,7; -2,5 (-45,5%) p<0,001]; ACT [T0=18,0 ± 5,6; T1=23,0 ± 2,6; +5,0 (+27,0%) p<0,001]; FEV1 [T0=86% ± 21; T1=108% ± 28; +22,0% p<0,001] (Figure 1). Discussion: Our study shows anti-IL4Rα treatment efficacy, both on clinical and QoL parameters. If confirmed in a larger cohort, these data could open a new scenario in patients affected by CRSwNP and asthma resistant to conventional treatment. References 1. Laidlaw TM, Mullol J, Woessner KM, Amin N, Mannent LP (2021) Chronic Rhinosinusitis with Nasal Polyps and Asthma. J allergy Clin Immunol Pract 9: 1133–1141. 2. Blauvelt A, de Bruin-Weller M, Gooderham M, Cather JC, Weisman J, et al. (2017) Long-term management of moderateto- severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet 389: 2287-2303.

HTML